Clinical Evidence in FDA Drug Approvals Varies Widely

Modern Healthcare, January 22, 2014. “With new drugs, there is often an exaggeration of the benefits and underreporting of the risks,” said Diana Zuckerman, NCHR president, who has testified at several hearings on drug safety. “There’s so much emphasis on drugs being the latest, the most innovative and novel—but unfortunately this usually means it’s just new, not necessarily better.”

Read More »

BPA-Free Baby Bottles Now Law, But We’re Not in the Clear

The Huffington Post, August 14, 2012. Diana Zuckerman, NCHR President, on the substitutes being used in place of BPA: “We are very concerned that BPA could be replaced with products that are just as risky, or even more risky. The federal government is not doing what is needed to protect the American public, either in their regulation of BPA or any of these potential substitutes.”

Read More »

How A Recalled Medical Device Killed A Vet At Seattle’s VA Hospital

KUOW, December 5, 2013. When Eddie Creed died at the Veterans Affairs hospital on Beacon Hill last year, his death certificate said throat cancer had killed him. But a KUOW investigation reveals what his doctors knew: A medical device called an Infusomat, which had been recalled the month before, ended his life. “Sadly, we actually have much more access to information about defective toasters, and certainly defective cars, than we seem to about defective medical devices,” said Diana Zuckerman, who heads the National Research Center for Women and Families in Washington, D.C.

Read More »

New Scrutiny for Medical Devices

New York Times, November 18, 2013. “People would be shocked to know that the F.D.A. never got its act together to require the studies,” said Diana Zuckerman, president of the National Research Center for Women and Families.

Read More »